Cancer Biomarkers Market
完整報告名稱與涵蓋範圍
Cancer Biomarkers Market Size, Share & Trends Analysis Report, By Biomarker Type (Genetic Biomarkers, Protein Biomarkers, Epigenetic Biomarkers, Metabolic Biomarkers), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Blood Cancers), By Application, By Region, and Segment Forecasts, 2026-2035
報告摘要
Cancer biomarkers are measurable molecular indicators, spanning gene mutations and fusions, protein antigens, methylation patterns, and metabolic signatures, that reveal the presence, behavior, or drug sensitivity of a tumor. This report covers the assays, platforms, and testing services that detect these markers across tissue and liquid specimens, from single-analyte immunoassays to comprehensive genomic profiling panels.
Growth is structurally tied to precision oncology: every newly approved targeted therapy or immunotherapy with a biomarker-defined label expands the tested population, making companion diagnostics a rising share of oncology testing volume. Liquid biopsy is the most consequential technology shift, as circulating tumor DNA assays move beyond therapy selection into minimal residual disease monitoring and multi-cancer early detection, converting one-time tests into recurring surveillance revenue. Methylation-based markers are gaining ground in screening for colorectal and other cancers, while quantitative protein markers retain their role in prostate and ovarian disease management. Reimbursement decisions and regulatory frameworks for laboratory-developed tests remain the principal gating factors for adoption.
North America leads on account of early payer coverage for genomic profiling and dense oncology trial activity, Europe follows with country-by-country reimbursement variation, and Asia Pacific is accelerating as China and Japan expand access to targeted therapies that require biomarker confirmation. The competitive environment blends diversified diagnostics majors with sequencing platform providers and focused liquid biopsy specialists.
The InsightAce study delivers revenue forecasts in US$ for all biomarker type, cancer type, application, and regional segments over 2026-2035, together with segment trend analysis, competitive landscape evaluation, and company profiles.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cancer Biomarkers Market Snapshot
Chapter 4. Global Cancer Biomarkers Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Biomarker Type Estimates & Trend Analysis
5.1. Biomarker Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Biomarker Type:
5.2.1. Genetic Biomarkers
5.2.2. Protein Biomarkers
5.2.3. Epigenetic Biomarkers
5.2.4. Metabolic Biomarkers
Chapter 6. Market Segmentation 2: By Cancer Type Estimates & Trend Analysis
6.1. Cancer Type & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Cancer Type:
6.2.1. Breast Cancer
6.2.2. Lung Cancer
6.2.3. Colorectal Cancer
6.2.4. Prostate Cancer
6.2.5. Blood Cancers
6.2.6. Other Cancers
Chapter 7. Market Segmentation 3: By Application Estimates & Trend Analysis
7.1. Application & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Application:
7.2.1. Diagnostics
7.2.2. Prognostics
7.2.3. Companion Diagnostics and Treatment Selection
7.2.4. Risk Assessment and Screening
Chapter 8. Cancer Biomarkers Market: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. United States
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. United Kingdom
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia Pacific
8.3.1. China
8.3.2. Japan
8.3.3. India
8.3.4. South Korea
8.3.5. Australia
8.3.6. Southeast Asia
8.3.7. Rest of Asia Pacific
8.4. Latin America
8.4.1. Brazil
8.4.2. Mexico
8.4.3. Rest of Latin America
8.5. Middle East & Africa
8.5.1. GCC Countries
8.5.2. South Africa
8.5.3. Rest of Middle East & Africa
Chapter 9. Competitive Landscape
9.1. Company Market Positioning Analysis
9.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 10. Company Profiles
10.1. F. Hoffmann-La Roche
10.2. Abbott Laboratories
10.3. Thermo Fisher Scientific
10.4. Illumina
10.5. QIAGEN
10.6. Agilent Technologies
10.7. Bio-Rad Laboratories
10.8. Hologic
10.9. Myriad Genetics
10.10. Exact Sciences
10.11. Guardant Health
10.12. Foundation Medicine
10.13. Natera
10.14. Siemens Healthineers
圖表清單 List of Tables & Figures
Table 1. Global Cancer Biomarkers Market Revenue Forecast by Biomarker Type, 2026-2035 (US$ Mn)
Figure 1. Global Cancer Biomarkers Market Segmentation Overview
Table 2. Global Cancer Biomarkers Market Revenue Forecast by Cancer Type, 2026-2035 (US$ Mn)
Figure 2. Global Cancer Biomarkers Market Share by Biomarker Type, 2026 & 2035
Table 3. Global Cancer Biomarkers Market Revenue Forecast by Application, 2026-2035 (US$ Mn)
Figure 3. Liquid Biopsy and Minimal Residual Disease Testing Adoption Trend Analysis
Table 4. North America Cancer Biomarkers Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 4. Global Cancer Biomarkers Market Share by Application, 2026 & 2035
Table 5. Europe Cancer Biomarkers Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Companion Diagnostics Approval Pipeline Impact Assessment
Table 6. Asia Pacific Cancer Biomarkers Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Asia Pacific Cancer Biomarkers Growth Opportunity Analysis
Table 7. Latin America Cancer Biomarkers Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Multi Cancer Early Detection Screening Outlook by Region
Table 8. Middle East & Africa Cancer Biomarkers Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Competitive Positioning of Key Cancer Biomarkers Participants
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們